drug · antibody drug conjugate
sacituzumab tirumotecan
Phase 3updated 6mo agoby $MRK Merck & Co., Inc.🔗 ChEMBL
Phase 3community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.
indications
indications
NSCLCBreast Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying sacituzumab tirumotecan
- phase3A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- phase3A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- phase2Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- phase3A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- phase3A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- phase3A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- phase3A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- phase2A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
News(10)
- Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launchPfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund development of its monthly GLP-1 receptor agonist.fiercebiotech · 7d ago
- 6 potential blockbusters that could pave China’s path to 2030 ambitionsIn its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…biospace · 15d ago
- Merck looks ahead to ‘another year of investment’ as Keytruda cliff loomsOn its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertensi…biospace · 21d ago
- From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data dramaEvery ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly anticipated phase 3 data for Moderna and Merck & Co.’s cancer vaccine were leaked…fiercebiotech · 23d ago
- ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancerSac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first…biospace · 24d ago
- STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancerA Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer.stat · 24d ago
- ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP saysAt the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Al…biospace · 28d ago
- Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xV…biospace · 1mo ago
- Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADCMerck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Ca…biospace · 1mo ago
- Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emergeAnalysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.biospace · 1mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that